Raymond James Financial
CANC icon

Raymond James Financial’s Tema Oncology ETF CANC Stock Holding History

Raymond James Financial’s Portfolio CANC Stock Details CANC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-875
Closed -$21.6K – 5243
2025
Q2 		$21.6K Buy
+875
New +$21K ﹤0.01% 5569

Other funds holding CANC

Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TCM
TD Capital Management Memphis, Tennessee $1.22B AUM 13.44% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $8.31B AUM 21.94% 1-Year Est. Return

Raymond James Financial's CANC Position: Q3 2025 in Review

Raymond James Financial sold out of Tema Oncology ETF (CANC) in Q3 2025, closing a stake of 875 shares — an estimated $21.6K sold.

Raymond James Financial first reported a position in CANC in Q2 2025 and held it in 1 quarter. The position peaked at $21.6K in Q2 2025. 6 funds tracked by Wall St. Rank hold CANC as of Q3 2025.

  • Raymond James Financial reported no remaining Tema Oncology ETF position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 875 Tema Oncology ETF shares in Q3 2025, an estimated $21.6K.
  • Raymond James Financial first reported a position in Tema Oncology ETF in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Tema Oncology ETF position peaked at $21.6K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Tema Oncology ETF as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.